EMB07

DRUG2 trials

Sponsors

EpimAb Biotherapeutics (Suzhou)Co., Ltd., Shanghai EpimAb Biotherapeutics Co., Ltd.

Conditions

Advanced/Metastatic Solid TumorsAggressive B-Cell Non-Hodgkin LymphomaCombination TherapyEMB07Relapse/Refractory LymphomaphaseI/II

Phase 1

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

RecruitingNCT05607498

EpimAb Biotherapeutics (Suzhou)Co., Ltd.Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma

Start: 2023-03-01End: 2026-03-31Target: 150Updated: 2025-03-03

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

RecruitingNCT07432022

Shanghai EpimAb Biotherapeutics Co., Ltd.Aggressive B-Cell Non-Hodgkin Lymphoma, Combination Therapy, EMB07 +1

Start: 2026-04-01End: 2028-06-30Target: 115Updated: 2026-09-01

Related Papers

Abstract LB126: Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release

Cancer Research2024-04-054 citations